Silver Book Fact

Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.

Lindsay R, Pack S, Li Z. Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis. Osteoporos Int. 2005; 16(3): 306-12. http://www.ncbi.nlm.nih.gov/pubmed/15455193

Reference

Title
Longitudinal Progression of Fracture Prevalence through a Population of Postmenopausal Women with Osteoporosis
Publication
Osteoporos Int
Publication Date
2005
Authors
Lindsay R, Pack S, Li Z
Volume & Issue
Volume 16, Issue 3
Pages
306-12
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • 30 drugs are currently in development for osteoporosis.  
  • Hip fracture prevention in at-risk, postmenopausal women saves $333 million annually.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…